Study of Citicoline for the Treatment of Traumatic Brain Injury (COBRIT) (COBRIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00545662|
Recruitment Status : Terminated (Trial stopped due to futility.)
First Posted : October 17, 2007
Results First Posted : December 19, 2012
Last Update Posted : December 19, 2012
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Drug: Placebo Drug: citicoline||Phase 3|
Traumatic brain injury (TBI) is a major cause of death and disability. In the United States alone approximately 1.4 million sustain a TBI each year, of which 50,000 people die, and over 200,000 are hospitalized. Despite numerous prior clinical trials no standard pharmacotherapy for the treatment of TBI has been established in either the acute or post acute setting. Citicoline is a naturally occurring endogenous compound. This compound offers the potential of employing neuroprotection, neuro-recovery and neurofacilitation to enhance recovery after TBI.
The primary goal of this study is to assess the efficacy of citicoline compared to placebo on functional and cognitive outcome in participants with traumatic brain injury.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1213 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Citicoline Brain Injury Treatment Trial|
|Study Start Date :||July 2007|
|Actual Primary Completion Date :||May 2011|
|Actual Study Completion Date :||May 2011|
Placebo tablets formulated to resemble the citicoline treatment.
Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
Experimental treatment administered orally or enterally depending upon whether the participant can swallow at 1,000 mg twice a day for 90 days or until the 90-day outcome assessment.
1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
Other Name: CDP-Choline, Cytidine 5-diphosphocholine, Somazina
- Functional and Cognitive Outcome [ Time Frame: 90 days ]The primary outcome of this study was analyzed using a global statistic of the Network Core Battery. There were 9 scales: California Verbal Learning Test II (CVLT-II); Controlled Oral Word Association Test (COWAT); Digit Span (DS); Glasgow Outcome Scale Extended (GOSE); Processing Speed Index (PSI); Stroop Test 1 and 2 (ST1&2); and Trail Making Test part A and B (TMT parts A and B). Each scale was assigned cut-off for good outcome: GOSE>7, CVLT>36, PSI>85, TMT part A <42, TMT part B<138.1, DS>7.15, ST1<60.29, ST2<151.47, COWAT>32.5. Logistic regression was used to estimate the global OR.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00545662
|United States, Alabama|
|University of Alabama at Birmingham|
|Birmingham, Alabama, United States, 35294-3295|
|United States, Maryland|
|University of Maryland, Baltimore|
|Baltimore, Maryland, United States, 21201|
|United States, Pennsylvania|
|Philadelphia, Pennsylvania, United States, 19141-3099|
|University of Pittsburgh|
|Pittsburgh, Pennsylvania, United States, 15213-3221|
|United States, Tennessee|
|University of Tennessee Health Sciences Center|
|Memphis, Tennessee, United States, 38163|
|United States, Texas|
|University of Texas, Southwestern Medical Center|
|Dallas, Texas, United States, 75390|
|United States, Virginia|
|Virginia Commonwealth University|
|Richmond, Virginia, United States, 23298-0677|
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 23298-0631|
|Principal Investigator:||Sherry Melton, MD||University of Alabama at Birmingham|
|Principal Investigator:||Howard Eisenberg, MD||University of Maryland|
|Principal Investigator:||Jack Jallo, MD, PhD||Temple University|
|Principal Investigator:||Joseph Ricker, PhD||University of Pittsburgh|
|Principal Investigator:||Shelly Timmons, MD, PhD||University of Tennessee Health Sciences Center|
|Principal Investigator:||Ramon Diaz-Arrastia, MD, PhD||University of Texas Southwestern Medical Center|
|Principal Investigator:||John Ward, MD||Virginia Commonwealth University|
|Principal Investigator:||Nancy Temkin, PhD||University of Washington|
|Study Director:||Beth Ansel, PhD||National Institute of Child Health and Human Development, National Center for Medical Rehabilitation Research|
|Principal Investigator:||William Friedewald, MD||Columbia University Department of Biostatistics|